Neuromuscular transmission and its pharmacological blockade. Part 1: Neuromuscular transmission and general aspects of its blockade

Pharmacy World and Science

Volumn 19, Issue 1, 1997, Pages 1-12

  Booij, Leo H D J ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

muscle relaxants; neuromuscular blockade; neuromuscular junction; neurotoxins; pharmacodynamics; pharmacokinetics

Indexed keywords

ATRACURIUM; CHOLINERGIC RECEPTOR; DOXACURIUM; FAZADINIUM; GALLAMINE; MIVACURIUM; MUSCLE RELAXANT AGENT; NEUROMUSCULAR BLOCKING AGENT; PANCURONIUM; ROCURONIUM; SUXAMETHONIUM; TOXIN; TUBOCURARINE CHLORIDE; VECURONIUM;

HUMAN; MUSCLE RELAXATION; NERVE ENDING; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; NONHUMAN; PHARMACODYNAMICS; REVIEW; STEREOISOMERISM;

DOWN-REGULATION; HUMANS; MUSCLE RELAXANTS, CENTRAL; NEUROMUSCULAR DEPOLARIZING AGENTS; NEUROMUSCULAR JUNCTION; NEUROMUSCULAR NONDEPOLARIZING AGENTS; RECEPTORS, CHOLINERGIC; STEREOISOMERISM; SYNAPTIC TRANSMISSION; UP-REGULATION;

EID: 0030904934     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008694726564     Document Type: Review

References (159)

1. Desaki J, Uehara Y. The overall morphology of neuromuscular junctions as revealed by scanning electron microscopy. J Neurocytol 1981;10:101-10.
2. Jasmin BJ, Lee RK, Rotundo RL. Compartmentalization of acetylcholinesterase mRNA and enzyme at the vertebrate neuromuscular junction. Neuron 1993;11:467-77.
3. Fernandez HL, Donoso JA. Exercise selectively increases G4 Ache activity in fast-twitch muscle. J Appl Physiol 1988;65:2245-52.
4. Massoulié J, Bon S. The molecular forms of cholinesterase and acetylcholinesterase in vertebrates. J Neurosci 1982;5: 1180-7.
5. Taylor P. The cholinesterases. J Biol Chem. 1991;266:4025-8.
6. Massoulié J, Pezzementi L, Bon S, Krejci E, Vallette FM. Molecular and cellular biology of cholinesterase. Prog.Neurobiol. 1993;13:31-91.
7. Wright DL, Plummer DT. Multiple forms of acetylcholinesterase from human erythrocytes. Biochem J 1973;133:521-7.
8. Weiler M, Roed IS, Whittaker VP. The kinectics of acetylcholine turnover in a resting cholinergic nerve terminal and the magnitude of the cytoplasmic compartment. J Neurochem 1982;38:1187-91.
9. Tucek S, Cheng SC. Provenance of the acetyl group of acetylcholine and experimentations of acetyl-CoA and Krebs cycle intermediates in the brain in vivo J Neurochem 1974;22:893-914.
10. Haga T, Noda H. Choline uptake systems of rat brain synaptosomes. Biochem Biophys Acta 1973;291:564-75.
11. 14C]acetylcholine in isolated rat diaphragm muscles. J Physiol 1970;206:145-66.
12. Yamamura HI, Snyder SH. Choline: high affinity uptake by rat synaptosomes. Science 1972;178:626-8.
13. Barker LA, Mittag TW. Comparative studies of substrates and inhibitors of choline transport and choline acetyltransferase. J Pharmacol Exp Ther 1975;192:86-94.
14. Tucek S. The synthesis of acetylcholine in skeletal muscles of the rat. J Physiol 1982;322:53-69.
15. Bonner TI, Erikson JD. Molecular biology of the vesicular ACh transporter. Trends Neurosci 1995;18:218-24.
16. Parsons SH, Prior C, Marshall IG. Acetylcholine transport, storage, and release. Int Rev Neurobiol 1993;35:279-390.
17. Searl T, Prior C, Marshall IG. The effects of L-vesamicol, an inhibitor of vesicular acetylcholine uptake, on two populations of miniature endplate currents at the snake neuromuscular junction. Neurosci 1990;35:145-56.
18. Kelly RB. Storage and release of neurotransmitters. Neuron 1993;10:43-53.
19. Fertuck HC, Salpeter MM. Localization of acetylcholine receptor by 1251-labeled α-bungarotoxin binding at mouse motor end-plate. Proc Natl Acad Sci USA 1974;72:1376-8.
20. Daniels MP, Vogel Z. Immunoperoxidase staining of α-bungarotoxin binding sites in muscle end-plates shows distribution of acetylcholine receptors. Nature 1975;254:339-41.
21. Yorifuji H, Hirokawa N. Cytoskeletal architecture of neuromuscular junction: Localization of vesicles. J Electron MicroscTech 1989;12:160-71.
22. Katz B, Miledi R R. The measurement of synaptic delay, and the time course of acetylcholine release at the neuromuscular junction. Proc R Lond Biol Sci 1965;161:483-95.
23. Katz B, Miledi R. The effect of temperature on the synaptic delay at the neuromuscular junction. J Physiol (Lond.) 1965;181:656-70.
24. Silinsky EM. The biophysical pharmacology of calcium dependent avetylcholine secretion. Pharmacol Rev 1985;37: 81-132.
25. Parnas H, Parnas I, Segel LA. On the contribution of mathematical models to the understanding of neurotransmitter release. Int Rev Neurobiol 1990;32:1-50.
26. Kelly RB. Storage and release of neurotransmitters. Neuron 1993;10:43-53.
27. De Camilli P. Molecular mechanisms in synaptic vesicle recycling. FEBS Letters 1995;369:3-12.
28. Greengard P, Valtorta F, Czernik AJ, Benfenati F. Synaptic vesicle phosphoproteins and regulation of synaptic function. Science 1993;259:780-5.
29. Smith SJ, Buchanan HJ, Ossess LR, Charlton MP, Augustine GJ. The spatial distribution of calcium signals in squid presynaptic terminals. J Physiol 1993;472:573-93.
30. Robitaille R, Adler EM, Charlton MP. Strategic location of calcium channels at transmitter release sites of frog neuromuscular synapses. Neuron1990;5:773-9.
31. Robinson MS. The role of clathrin, adaptors and dynamin in endocytosis. Curr Opin Cell Biol 1994;6:538-44.
32. McPherson P, De Camilli P. Sem.Neurosci. 1994;6:137-47.
33. Fesce R, Grohovaz F, Valtorta F, Meldolesi J. Neurotransmitter release: fusion or 'kiss-and-run'? Trends Cell Biol 1994;4:1-4.
34. van der Bliek AM, Redelmeier TE, Damke H, Tisdale EJ, Meyerowitz EM, Schmid SL. Mutations in human dynamin block: an intermediate stage in coated vesicle formation. J Cell Biol 1993;122:553-63.
35. Takei K, McPherson P, Schmid SL, DeCamilli P. Tubular membrane invaginations coated by dynamin rings are induced by GTP-γ-S in nerve terminals. Nature 1995;374:186-90.
36. Regnier-Vigouroux A, Tooze SA, Huttner WB. Newly synthetized synaptophtysin is transported to synaptic-like microvesicles via constitutive secetrory vesicle and the plasma membrane. EMBO J. 1991;10:3589-601.
37. De Camilli P, Benfenati F, Valtorta F, Greengard P. The synapsins. Ann Rev Cell Biol 1990;6:433-60.
38. Hurlbut WP, lezzi N, Fesce R, Ceccarelli B. Correlation between quantal secretion and vesicle loss at the frog neuromuscular junction. J Physiol 1990;425:501-26.
39. Khanin R, Parnas H, Segel L. Diffusion cannot given govern the discharge of neurotransmitter in fast synapses. Biophys J 1994;67:966-72.
40. Vizi ES, Vyskocil F. Changes in total and quantal release of acetylcholine in the mouse diaphragm during activation and inhibition of membrane ATPase. J Physiol (Lond.) 1979; 286;1-14.
41. Dunant Y. On the mechanism of acetylcholine release. Progr Neurobiol 1986;26:55-92.
42. Glavonoviç MI, Narahashi T. Depression, recovery and facilitation of neuromuscular transmission during prolonged tetanic stimulation. Neurosci 1988;25:271-81.
43. Weiler M, Roed IS, Whittaker VP. The kinetics of acetylcholine turnover in a resting cholinergic nerve terminal and the magnitude of the cytoplasmic compartment. J Neurochem 1982;38:1187-91.
44. Bowman WC. Prejunctional and postjunctional cholinoreceptors at the neuromuscular junction. Anesth Analg 1980;59:935-43.
45. D'Agostino G, Chiari MC, Grana E, Subissi A, Kilbinger H. Muscarinic inhibition of acetylcholine release from a novel in vitro preparation of the guinea-pig trachea. Naun Schmiedeberg's Arch Pharmacol 1990;342:141-45.
46. Molenaar PC, Polak AL. Stimulation of atropine on acetylcholine release and synthesis in cortical slices from rat brain. Br J Pharmacol 1970;40:406-17.
47. Aas P, Fonnum F. Presynaptic inhibition of acetylcholine release. Acta Physiol Scand 1986;127:335-42.
48. Deneris ES, Connolly J, Rogers SW, Duvoisin R. Pharmacological and functional diversity of neuronal nicotinic actylcholine receptors. Trends Parharmacol Sci 1991; 12:34-40.
49. Wessler I, Halank M, Rasbach J, Kilbinger H. Presynaptic nicotine receptors mediating a positive feedback on transmitter release from the rat phrenic nerves. Naun Schmiedeberg's Arch Pharmacol 1986;334:365-72.
50. Wessler I. Control of transmitter release from the motor nerve by presynaptic nicotinic and muscarinic autoreceptors. Trends Pharmaco Sci 1989;10:110-14.
51. Reynolds J, Karlin A. Molecular weight in detergent solution of acetylcholine receptor from torpedo californica. Biochemistry 1978;17:2035-38.
52. Raftery MA, Hunkapiller MW, Strader CD, Hood LE. Acetylcholine receptor: Complex of homologous subunits. Science 1980;208:1454-57.
53. Martinou JC, Merlie JP. Nerve-dependent modulation of acetylcholine receptor epsilon-subunit gene expression. J Neurosci 1991;11:1291-9.
54. Falls DI, Rosen Km, Corfas G, Lane WS, Fischbach GD. ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the Neu ligand family. Cell 1993;72:801-15.
55. Sandrock AW, Gosdearl ADJ, Yin Q-W, Chang D, Fischbach GD. ARIA is concentrated in the nerve terminals at neuromuscular junctions and at other synapses. J Neurosci 1995;15:124-36.
56. Murray N, Zheng YC, Mandel G, Brehn P, Bolinger R, Reuer Q, Kullbergh R. A single site on the ε subunit is responsible for the change in Ach receptor channel conductance during skeletal muscle development. Neuron 1995;14:865-70.
57. Moscoco LM, Chu GC, Gautam M, Noakes PG, Merlie JP, Danes JR. Synapse-associated expression of an acetylcholine receptor-inducing protein. ARIA/Hergulin, and its putative receptors, ErbB2 and ErbB3, in developing mammalian muscle. Devel Biol 1995;172:158-69.
58. Steinbach JG, Ifune C. How many kinds of nicotinic acetylcholine receptors are there? Trends Neurosci. 1989;12:3-6.
59. Anderson DG, Blobel G. In vitro synthesis, glycosylation and membrane insertion of the four subunits of Torpedo acetylcholine receptor. Proc Natl Acad Sci USA 1981;78:5598-602.
60. McCrea PD, Popot K, Engelman DM. Transmembrane topography of the nicotinic acetylcholine receptor delta subunit. EMBO J 1987;6:1319-26.
61. Levitt TA, Salpeter MM. Denervated endplates have a dual population of junctional acetylcholine receptors. Nature 1981;291:239-41.
62. Fontaine B, Klarsfeld A, Changeux JP. Calcitonin gene-related peptide and muscle activity regulate acetylcholine receptor α-subunit mRNA levels by distinct intracellular pathways. J Cell Biol 1987:1337-42.
63. Markelonis GJ, Oh TO, Derr D. Stimulation of protein synthesis in cultered skeletal muscle by a trophic protein from sciatic nerves. Exp Neurol 1980;70:598-612.
64. McMahan UJ, Horton SE, Werle MJ, Honig LS, Kroger S, Ruess MA, Escher G. Agrin isoforms and their role in synaptogenesis. Curr Opin Cell Biol 1992;4:869-74.
65. Patrick J, Séquéla P, Vernino S, Amador M, Luetje C, Dani JA. Functional diversity of neuronal nicotinic acetylcholine receptors. Prog Brain Res 1993;98:113-20.
66. Apel ED, Roberds SL, Campbell KP, Merlie JP. Rapsyn may function as a link between the acetylcholine receptor and the agrin-binding dystrophin-associated glycoportein complex. Neuron 1995;15:115-26.
67. Dwyer TM, Adams DJ, Hille B. The permeability of the endplate channel to organic cations in frog muscle. J Gen Physiol 1980;75:469-92.
68. Klymkowsky MW, Stroud RM. Immunospecific identification and three dimensional structure of a membrane-bound acetylcholine receptor Torpedo californica. J Mol Biol 1979; 128:319-34.
69. Mitra AK, McCarthy MP, Stroud RM. Three dimensional structure of the nicotinic acetylcholine receptor and location of the major associated 43-kD cytoskeletal protein, determined at 22 Å by low dose electron microscopy and x-ray diffraction to 12.5 Å. J Cell Biol 1989;109:755-74.
70. Cash DJ, Hess GP. Molecular mechanisms of acetylcholine receptors-controlled ion translocation across cell membranes. Proc Natl Acad Sci USA 1980;77:842-46.
71. Raftery MA, Conti-Tronconi BM, Dunn SMJ. Structural and functional aspects of the nicotinic acetylcholine receptor. Fund Appl Toxicol 1985;5:S39-S46.
72. Smith MM, Lindstrom J, Merlie JP. Formation of the α-bungarotoxin binding site and assembly of the nicotinic acetylcholine receptor subunits occurs in the endoplasmic reticulum. J Biol Chem 1987;262:4367-76.
73. Devreotes PN, Gardner JM, Fambrough DM. Kinetics of biosynthesis of acetylcholine receptor and subsequent incorporation into plasma membrane of cultured chick skeletal muscle. Cell 1977;10:365-73.
74. Merlie JP, Isenberg K, Carlin B, Olson EN. Regulation of syntyhesis of acetylcholine receptors. Trends Pharmacol Sci 1984;377-9.
75. Merlie JP, Isenberg KE, Russell SD, Sanes JR. Denervation supersensitivity in skeletal muscle: Analysis with a cloned cDNA probe. J Cell Biol 1984 99:332-5.
76. Illingworth JA. Muscle biochemistry. Br J Anaesth 1980;52: 123-8.
77. Floyd K. The physiology of striated muscle. Br J Anaesth 1980;52:111-21.
78. Paton WD, Waud DR. The margin of safety of neuromuscular transmission. J Physiol (Lond) 1967;191:59.
79. Paton WD, Waud DR. The margin of safety of neuromuscular transmission. J Physiol (Lond) 1967;191:59-90.
80. Robinson DS, McGee R. Agonist-induced regulation of the neuronal nicotinic acetylcholine receptor of PC12 cells. Mol Pharmacol 1985;27:409-17.
81. Berg DK, Boyd RT, Halvorsen SW, Higgins LS, Jacob MK, Margiotta F. Regulating the number and function of neuronal acetylcholine receptors. Trends Neurosci 1989;12:16-26.
82. Benwell MEM, Balfour DJK, Anderson JM. Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain. J Neurochem 1988;50:1243-7.
83. Wonnacott S. The paradox of nicotinic acetylcholine receptor upregulation by nicotine. Trends Pharmacol Sci 1990;11: 216-9.
84. Schwartz RD, Kellar KJ. In vivo regulation of [sH]acetylcholine recognition sites in brain by nicotinic cholinergic drugs. J Neurochem 1985;42:483-91.
85. Costa LG, Murphy SD. [3H]Nicotinic binding in rat brain: alteration after chronic acetylcholine esterase inhibition. J Pharmacol Exp Ther 1983;226:392-7.
86. Martyn JAJ, White DA, Gronert GA, Jaffe RS, Ward JM. Up-and-down regulation of skeletal muscle acetylcholine receptors. Anesthesiology 1992;76:822-43.
87. Hogue Jr, CW, Ward JM, Itani MS, Martyn JAJ. Tolerance and upregulation of acetylcholine receptors follow chronic infusion of d-tubocurarine. J Appl Physiol 1992;72:1326-31.
88. Horton WA, Fergusson NV. Hyperkalemia and cardiac arrest after the use of suxamethonium in intensive care. Anaesthesia 1988;43:890-1.
89. Laylock JRD, Loughman E. Suxamethonium-induced hyperkalemia following cold injury. Anaesthesia 1986;41:739-41.
90. Gupta RS, Dettborn WD, Patterson GT. Mechanisms of toxicity and tolerance to disopropylphosphoro-fluoridate at the neuromuscular junction. Toxicol Appl Pharmacol 1986;84: 541-50.
91. Wessler I. Control of transmitter release from the motor nerve by presynaptic nicotinic and muscarinic autoreceptors. Trends Pharmaco Sci 1989;10:110-14.
92. Prior C, Tian L, Dempster J, Marshall IG. Prejunctional actions of muscle relaxants: synaptic vesicles and transmitter mobilization as sites of action. Gen Pharmacol 1995;26:659-66.
93. Bowman WC. Prejunctional and postjunctional cholinoceptors at the neuromuscular junction. Anesth Analg 1980;59: 935-43.
94. Foldes FF, Chaudry IA, Kinjo M, Nagashima H. Inhibition of mobilization of acetylcholine. Anesthesiology 1989;71:218-23.
95. Bowman WC, Prior C, Marshall IG. Presynaptic receptors in the neuromuscular junction. Ann NY Acad Sci 1990;604: 69-81.
96. Williams NE, Webb SN, Calvey TN. Differential effects of myoneural blocking drugs on neuromuscular transmission. Br J Anaesth 1980;52:1111-14.
97. Tian L, Prior C, Dempster J, Marshall IG. Nicotinic antagonist-produced frequency-dependent changes in acetylcholine release from rat motor nerve terminals. J Physiol (Lond) 1994;476:517-29.
98. Wilson DF, Thomsen RH. Effects of hexamethonium on transmitter release from the rat phrenic nerve. Neurosci Letters 1992;143:79-82.
99. Silinsky EM. The biophysical pharmacology of calcium-dependent acetylcholine secretion. Pharmac Rev 1985;37: 81-132.
100. Meldolesi J, Scheer H, Madeddu L. Mechanism of action of α-latrotoxin: the presynaptic stimulatory toxin of the black widow spider venom. Trends Pharmacol Sci 1986;7:151-155.
101. Waud BE, Waud DR. The margin of safety of neuromuscular transmission in the muscle of the diaphragm. Anesthesiology 1972;37:413-16.
102. Bowman WC. Physiology and pharmacology of neuromuscular transmission, with special reference to the possible consequences of prolonged blockade. Intens Care Med 1993;19:S45-S53.
103. Shanks CA, Somogyi AA, Triggs EJ. Dose-response and plasma concentration-response relationship of pancuronium in man. Anesthesiology 1979;51:111-18.
104. Agoston S, Feldman SA, Miller RD. Plasma concentrations of pancuronium and neuromuscular blockade after injection into isolated arm, bolus injection, and continuous infusion. Anesthesiology 1979;51:119-22.
105. Shanks CA, Somogyi AA, Triggs EJ. Plasma concentrations of pancuronium during pre-determined intensities of neuromuscular blockade. Br J Anaesth 1978;235-8.
106. Stanski DR, Sheiner LB. Pharmacokinetics and dynamics of muscle relaxants. Anesthesiology 1979;51:103-5.
107. Lambert JJ, Durant NN, Henderson EG. Drug-induced modifications of ionic conductance at the neuromuscular junction. Ann Rev Pharmacol Toxicol 1983;23:505-39.
108. Thesleff S. the mode of neuromuscular block caused by acetylcholine, nicotine, decamethonium and succinylcholine. Acta Physiol Scand 1955;34:218-31.
109. Unwin N, Toyoshima C, Kubalek E. Arrangement of the acetylcholine receptor subunits in the resting and desensitized states, determined by cryoelectron microscopy of crystallized Torpedo postsynaptic membranes. J Cell Biol 1988; 107:1123-38.
110. Wachtel RE. Comparison of anticholinesterases and their effects of acetylcholine-activated ion channels. Anesthesiology 1990;70:405-10.
111. Payne JP, Hughes R, Al Azawi S. Neuromuscular blockade by neostigmine in anaesthetized man. Br J Anaesth 1980;52: 69-76.
112. Waud BE, Waud DR. The margin of safety of neuromuscular transmission in the muscle of the diaphragm. Anesthesiology 1972;37:413-16.
113. Bovet D, Depoierre F, Lestrange Y. Proprietes curarisantes des ethers phenoliques a fonctions ammonium quarternaires. Comptes Rendus Hebdomadaires de Sceances de l'Academie des Sciences 1947;225:74-76.
114. Lund I, Stovner J. Experimental and clinical experiences with a new muscle relaxant RO 4-3816, diallyl-nor-toxiferine. Acta Anaesthesiol Scand 1962;62:85-97.
115. Baird WLM, Reid AM. The neuromuscular blocking properties of a new steroid compound, pancuronium bromide. Br J Anaesth 1967;39:775-80.
116. Sobell HM, Sakore TD, Tavale SS, Canepa FG, Pauling P, et al. Stereochemistry of curare alkaloid: O,O',N-trimethyl-d-tubocurarine. Proc Natl Acad Sci USA 1972;69:2212-15.
117. Kimenis A, Klusha VE, Ginters YA. Pharmacology of Dioxonium, a new myorelaxant. Farmakologiya i toxicologiya 1972;35:172.
118. Simpson BR, Strunin L, Savege TM, Walton B, Foley ET, Maxwell MP, et al. An azobis-arylimidazo-pyridinium derivative: A rapidly acting non-depolarizing muscle-relaxant. Lancet 1972;1:516-19.
119. Marshall IG, Agoston S, Booij LHDJ, Durant NN, Foldes FF. Pharmacology of Org NC45 compared with other nondepolarizing neuromuscular blocking drugs. Br J Anaesth 1980;52:11S-19S.
120. Crul JF, Booij LHDJ. First clinical experiences with Org NC45. Br J Anaesth 1980;52 suppl:S49-52S.
121. Wierda JMKH, Richardson FJ, Agoston S. Dose response relation and time course of action of pipecuronium bromide in humans anaesthetized with nitrous oxide and isoflurane, halothane, or droperidol/fentanyl. Anesth Analg 1989;68: 208-13.
122. Payne JP, Hughes R. Evaluation of atracurium in anaesthetized man. Br J Anaesth 1981;53:45-54.
123. Basta SJ, Ali HH, Savarese JJ, Sunder N, Gionfriddo M, Cloutier G, Lineberry C, Cato AE. Clinical pharmacology of atracurium besylate (BW 33A): A new non-depolarizing muscle relaxant. Anesth Analg 1982;61:723-9.
124. Basta SWJ, Savarese JJ, Ali HH, Embree PB, Schwartz AF, Rudd GD, Wastlla WB. Clinical pharmacology of doxacurium chloride. Anesthesiology 1988;69:478-86.
125. Savarese JJ, Ali HH, Basta SJ, Embree PB, Scott RPF, Sunder N, Weakly JN, Wastlla WB, el-Sayad HA. The clinical neuromuscular pharmacology of mivacurium chloride (BW 1090U): A short acting ester neuromuscular blocking drug. Anesthesiology 1988;68:723-32.
126. Booij LHDJ, Knape JTA. The neuromuscular blocking effect of Org 9426. Anaesthesia 1991;46:341-3.
127. Gyermek L. Nguyen N, Lee C. GI-64, a new, rapidly acting nondepolarizing neuromuscular blocking agent. Anesthesiology 1990;73:A862.
128. Kharkevich DA. New curare-like agents. J Phar Pharmac 1974;26:153-65.
129. Gandiha A, Marshall IG, Paul D, Rodger IW, Scott W, Singh H. Some actions of chandonium iodide, a new short-acting muscle relaxant, in anesthetized cats and on isolated muscle preparations. Clin Exp Pharmacol Physiol 1975;2:150-70.
130. Baird WLM. Initial studies in man with a new myoneural blocking agent (Org 6368). Br J. Anaesth 1974;46:658-61.
131. Booij LHDJ, Crul JF, van der Pol F. Cardiovascular and neuromuscular blocking effects of four new muscle relaxants in anaesthetized Beagle dogs. Eur J Anaesthesiol 1988;6:70.
132. Muir AW, Houston J, Marshall RJ, Bowman WC, Marshall IG. A comparison of the neuromuscular blocking and autonomic effects of two new short-acting muscle relaxants with those of succinylcholine in the anesthetized cat and pig. Anesthesiology 1989;70:533-40.
133. Gilly H, Hirtschl MM, Steinbereithner K. Pharmacodynamics of Org 8764, atracurium and vecuronium: a comparison of vocal cord, diaphragm and tibial muscle relaxation. Anesthesiology 1988;69;A481.
134. Muir AW, Anderson K, Marshall RJ, Booij LHDJ, Crul JF, Prior C, Bowman WC, Marshall IG. The effects of a 16-N-homopiperidino analogue of vecuronium on neuromuscular transmission in anaesthetized cats, pigs, dogs an monkeys, and in isolated preparations. Acta Anaesthesiol Scand 1991;35:85-90.
135. Hughes R. Evaluation of the neuromuscular blocking properties and side-effects of the two new isoquinolinium bisquarternary compounds (BW 252C64 and BW 403C65). Br J Anaesth 1972;44:27-42.
136. Kimura M, Kimura I, Muroi M, Nojima H, Diwan PV. Depolarizing neuromuscular blocking action of coryneine derived from aconite root in isolated phrenic nerve-diaphragm muscles. Biol Pharm Bull 1995;18:691-5.
137. Tammisto T, Salmenpera M. Neuromuscular blocking properties of dioxonium. Acta Anaesth.Scand. 1980;24:439-43.
138. Salmenpera M, Tammisto T. The use of dioxonium as a neuromuscular blocking agent. Acta Anaesth Scand 1980;24: 395-8.
139. Bowman WC, Rodger IW, Houston J, Marshall RJ, Mclndewar I. Structure : action relationships among some desacetoxy analogues of pancuronium and vecuronium in the anesthetized cat. Anesthesiology 1988;69:57-62.
140. Maehr RB, Wastila WB. Comparative pharmacology of atracurium and six isomers in cats. Anesthesiology 1993;79: A946.
141. Law Min JC, Bakavac I, Glavinovic MI, Donati F, Bevan DR. lontophorectic study of speed of action of various muscle relaxants. Anesthesiology 1992;77:351-6.
142. Kim SY, Hwang KH, Ok SY, Kim SI, Kim SC, Park W. Discrepancy of recovery times related to potency between atracurium and mivacurium simultaneously administered in isolated forearms. Anaesthesia 1995;50:507-9.
143. Kopman AF. Pancuronium, gallamine and d-tubocurarine compared: is speed of onset inversely related to drug potency? Anesthesiology 1989;70:915-20.
144. Ramzan IM. Molecular weight of cation as a determinant of speed of onset of neuromuscular blockade. Anesthesiology 1982;57:247-48.
145. Blackburn CL, Morgan M. Comparison of speed of onset of fazadinium, pancuronium, tubocurarine and suxamethonium. Br J Anaesth 1978;50:361-4.
146. Mirakhur RK, Lavery GG, Clarke RSJ, Gibson FM, McAtees E. Atracurium in clinical anaesthesia: effect of dosage on onset, duration and conditions for tracheal intubation. Anaesthesia 1985;40:801-5.
147. Feldman S, Fauvel N, Harrop-Griffiths W. The onset of neuromuscular blockade. In: Bowman WC, Denissen PAF, Feldman S, eds. Neuromuscular blocking agents: past, present and future. Amsterdam: Excerpta Medica 1990 pp. 44-51.
148. Ginsberg B, Glass PS, Quill T, Shafron D, Ossey KD: Onset and duration of neuromuscular blockade following high-dose vecuronium administration. Anesthesiology 1989;71: 201-5.
149. Tullock WC, Diana P, Cook DR, Wilks DH, Brandom SW, Stiller RL, Beach CA. Neuromuscular and cardiovascular effects of high-dose vecuronium. Anesth Analg 1990;70: 86-90.
150. Glass PSA, Wilson W, Mace JA, Wagoner R: Is the priming principle both effective and safe? Anesth.Analg. 1989;68: 127-34.
151. Mirakhur RF, Lavery GG, Gibson FM, Clarke RS. Intubating conditions after vecuronium and atracurium given in divided doses (the priming principle). Acta Anaesthesiol Scand 1986;30:347-50.
152. Sosis M, Stiner A, Larijari GE, Marr AT. An evaluation of priming with vecurionium. Br J Anaesth 1987;59:1236-9.
153. Waud BE, Waud DR. Quantitative examination of the interaction of competitive neuromuscular blocking agents on the indirectly elicited twitch. Anesthesiology 1984;61:420-7.
154. Naguib M. Neuromuscular effects of rocuronium bromide and mivacurium chloride administered alone and in combination. Anesthesiology 1994;81:388-95.
155. Wood M. Plasma drug binding: implications for anaesthesiologists. Anesth Analg 1986;65:786-804.
156. Karalliedde L. Animal toxins. Br.J.Anaesth. 1995;74:319-27.
157. Schiavo G, Rossetto O, Montecucco C. Clostridial neurotoxins as tools to investigate the molecular events of neurotransmitter release. Semin Cell Biol 1994;5:221-9.
158. Henkel AW, Betz WJ. Monitoring of Black Widow Spider venom (BWSV) induced exo- and endocytosis in living frog motor nerve terminals with FM1-43. Neuropharmacol 1995;1397-1406.
159. Abramson SN, Febical W, Taylor P. Lophotoxins: irreversible active-site directed inhibitors of nicotinic acetylcholine receptors. Drug Devel Res 1991;24:297-312.